Lariam

Mefloquine, the active ingredient in Lariam, is a quinoline antimalarial presented as a tablet for oral use. It treats and prevents malaria infection in travelers and residents of endemic areas.

GNH USA supplies Lariam as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lariam is a quinoline antimalarial used to prevent and treat malaria infection. - Prevention of malaria infection: provides prophylaxis for travelers and residents in endemic regions. - Acute malaria caused by Plasmodium falciparum: clears blood‑stage parasites and resolves symptoms. - Acute malaria caused by Plasmodium vivax: eliminates blood‑stage parasites and aids recovery.

Mefloquine may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: transient sensation of light‑headedness. - Headache: occasional throbbing pain. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Neuropsychiatric reactions: anxiety, depression, or psychosis. - Seizures: rare convulsive events. - Cardiac arrhythmias: irregular heart rhythm, especially with QT‑prolonging agents. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Visual disturbances: blurred vision or loss of visual acuity.

Before prescribing mefloquine, consider patient history and potential risks. - Psychiatric history: assess for prior depression, anxiety, or psychosis. - Cardiac disease: use cautiously in patients with known arrhythmias. - Hypersensitivity: avoid in individuals with known allergy to quinoline antimalarials. - Pregnancy: not recommended unless benefits outweigh potential risks. - Liver function: monitor hepatic enzymes during prolonged therapy. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Mefloquine can interact with several medications, requiring careful management.

Major Interactions (Avoid): - Antacids: may reduce mefloquine absorption. - Strong CYP450 inhibitors: increase plasma concentrations, raising toxicity risk. - QT‑prolonging drugs: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Other antimalarials: potential additive toxicity. - Antidepressants: may exacerbate neuropsychiatric effects. - Alcohol: can enhance central nervous system side effects.